These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 10933062

  • 21. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 22. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    Jounaidi Y, Waxman DJ.
    Cancer Res; 2000 Jul 15; 60(14):3761-9. PubMed ID: 10919648
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
    Le QT, Kovacs MS, Dorie MJ, Koong A, Terris DJ, Pinto HA, Goffinet DR, Nowels K, Bloch D, Brown JM.
    Int J Radiat Oncol Biol Phys; 2003 Jun 01; 56(2):375-83. PubMed ID: 12738312
    [Abstract] [Full Text] [Related]

  • 24. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 26. DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).
    Chowdhury G, Junnotula V, Daniels JS, Greenberg MM, Gates KS.
    J Am Chem Soc; 2007 Oct 24; 129(42):12870-7. PubMed ID: 17900117
    [Abstract] [Full Text] [Related]

  • 27. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Oct 24; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 28. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P, Huang JM, Ren Y, Zha X, Deng BF, Wu JH, Lang JY.
    Chin J Cancer; 2010 Feb 24; 29(2):126-30. PubMed ID: 20109337
    [Abstract] [Full Text] [Related]

  • 29. Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.
    Maxim PG, Carson JJ, Ning S, Knox SJ, Boyer AL, Hsu CP, Benaron DA, Walleczek J.
    Radiat Res; 2004 Aug 24; 162(2):185-93. PubMed ID: 15387146
    [Abstract] [Full Text] [Related]

  • 30. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs).
    Elsaidi HR, Yang XH, Ahmadi F, Weinfeld M, Wiebe LI, Kumar P.
    Eur J Med Chem; 2019 Mar 01; 165():216-224. PubMed ID: 30684798
    [Abstract] [Full Text] [Related]

  • 31. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB, Brown JM.
    Cancer Res; 2002 Sep 15; 62(18):5248-53. PubMed ID: 12234992
    [Abstract] [Full Text] [Related]

  • 32. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.
    Hong B, Lui VW, Hui EP, Ng MH, Cheng SH, Sung FL, Tsang CM, Tsao SW, Chan AT.
    Invest New Drugs; 2011 Jun 15; 29(3):401-10. PubMed ID: 20013349
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
    el-Said A, Menke D, Dorie MJ, Brown JM.
    Radiat Oncol Investig; 1999 Jun 15; 7(3):163-9. PubMed ID: 10406058
    [Abstract] [Full Text] [Related]

  • 34. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Jun 15; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 35. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
    Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH.
    J Cancer Res Clin Oncol; 2008 Mar 15; 134(3):397-404. PubMed ID: 17724612
    [Abstract] [Full Text] [Related]

  • 36. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
    Goldberg Z, Evans J, Birrell G, Brown JM.
    Int J Radiat Oncol Biol Phys; 2001 Jan 01; 49(1):175-82. PubMed ID: 11163512
    [Abstract] [Full Text] [Related]

  • 37. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
    Masunaga S, Ono K, Hori H, Akaboshi M, Kawai K, Suzuki M, Kinashi Y, Kasai S, Nagasawa H, Uto Y.
    Radiat Med; 1998 Jan 01; 16(6):441-8. PubMed ID: 9929144
    [Abstract] [Full Text] [Related]

  • 38. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP, Abbattista MR, Anderson RF, Li D, Taghipouran R, Tsai A, Lee SJ, Smaill JB, Denny WA, Hay MP, Wilson WR, Hicks KO, Patterson AV.
    Molecules; 2020 Oct 22; 25(21):. PubMed ID: 33105798
    [Abstract] [Full Text] [Related]

  • 39. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Oct 22; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 40. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL.
    Br J Cancer; 1995 Mar 22; 71(3):529-36. PubMed ID: 7880735
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.